Antonio Diaz, MD
Family Medicine · Brownsville, TXNPI 1952582710
Payments from drug & device makers
Across 101 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$411
- Novo Nordisk$394
- Amarin Pharma, Inc.$360
- AbbVie$205
- AstraZeneca$201
- E.r. Squibb & Sons, L.L.C.$123
- plus $543 from 15 others
What the payments were for
- Food & beverage$2,237100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $411 |
| Novo Nordisk | 21 | $394 |
| Amarin Pharma, Inc. | 14 | $360 |
| AbbVie(2 entities) | 11 | $205 |
| AstraZeneca | 12 | $201 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| GSK | 6 | $116 |
| Nestle Healthcare Nutrition Inc. | 5 | $96 |
| Novartis | 2 | $49 |
| Bayer | 2 | $41 |
| Verona Pharma, Inc. | 1 | $30 |
| Pfizer | 2 | $28 |
| Shield Therapeutics Inc | 1 | $28 |
| Intuitive Surgical | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Amgen | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Si-bone, Inc. | 1 | $17 |
| Dentsply Sirona Inc | 1 | $17 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,237 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 195 | $307,800 |
| FarxigaDapagliflozin Propanediol | 258 | $257,726 |
| MounjaroTirzepatide | 155 | $190,617 |
| JardianceEmpagliflozin | 111 | $112,745 |
| RybelsusSemaglutide | 63 | $83,169 |
| VascepaIcosapent Ethyl | 100 | $74,189 |
| EliquisApixaban | 80 | $73,231 |
| TradjentaLinagliptin | 60 | $59,068 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $58,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $47,419 |
| XareltoRivaroxaban | 33 | $45,440 |
| Xigduo XrDapaglifloz Propaned/Metformin | 37 | $40,950 |
| JanuviaSitagliptin Phosphate | 26 | $40,685 |
| TrulicityDulaglutide | 23 | $40,458 |
| EntrestoSacubitril/Valsartan | 24 | $30,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $394 | $390,969258 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $201 | $279,503291 claims |
| Lilly USA, LLCMounjaro, Trulicity | $411 | $231,076178 claims |
| Boehringer IngelheimJardiance, Tradjenta | $22 | $171,813171 claims |
| PfizerEliquis | $28 | $73,23180 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $116 | $66,816104 claims |
| Johnson & JohnsonXarelto | $21 | $45,44033 claims |
| NovartisEntresto | $49 | $30,04824 claims |
| AbbVieLinzess | $205 | $25,72540 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $24,30729 claims |
| AmgenProlia | $20 | $18,43511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Brownsville
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.